New data suggests that the glucose-lowering drug class sodium-glucose cotransporter-2 (SGLT2) inhibitors appear to reduce the risk for recurrent gout flares – and to lessen excess mortality – in people with gout and Type 2 diabetes.
These results are important because current management of gout is suboptimal, with many patients either not receiving adequate urate-lowering therapies (such as allopurinol) or stopping taking them – often because of initial (but preventable) gout flare.
However, trials among nearly 6000 adults with both Type 2 diabetes and gout from a United Kingdom primary care database fond that SGLT2 inhibitor treatment was associated with 19% fewer recurrent gout flares and 29% lower mortality.Moreover, unlike other urate-lowering therapies, there were no apparent increases in the risk of gout flares after initiating therapy
In addition to lowering glucose, SGLT2 inhibitors also reduce the risk for major adverse cardiovascular events and all-cause mortality in people, regardless of their diabetes status.
To read more, CLICK HERE.